...and Domain Associates; new investor AKS Capital; and additional undisclosed investors participated in the close. Lithera Inc....

...and a 2-point improvement in CPnS score from baseline to week 9 vs. placebo (p<0.05). Lithera...
...Patients received placebo or 0.4, 1 or 4 µg LIPO-202 once weekly for 8 weeks. Lithera...
...and said data for the 1 and 4 µg doses of LIPO-202 were not disclosed. Lithera...

...Global Abdominal Profile Scale (P-GAPS) score and a 2-point improvement in Clinician Photo-numeric Scale (CPnS). Lithera...

...Venture Investment and Andrea Holdings. Undisclosed investors also participated. Lithera raised $20.6 million last December. Lithera Inc....

...for 8 weeks in about 500 healthy patients with subcutaneous fat in the periumbilical area. Lithera Inc....

...Raised: $20.6 million Investors: Rusnano; Domain Associates; Alta Partners; Amorepacific Ventures; Numoda Capital Innovations Note: Lithera...

...Numoda Capital Innovations. Lithera said the round may be increased to up to $35.6 million. Lithera's...
...salmeterol xinafoate , is in development to reduce abdominal bulging due to excess subcutaneous fat. Lithera...

...London, U.K.) markets Advair salmeterol/fluticasone propionate to treat chronic obstructive pulmonary disease (COPD) and asthma. Lithera Inc....